Molecular determinants of apoptosis induced by cytotoxic drugs

Klinische Padiatrie

Volumn 210, Issue 4, 1998, Pages 148-152

  Fulda, Simone ^a   Friesen, Claudia ^a   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; CD95; Drugs

Indexed keywords

CYTOTOXIC AGENT; DOXORUBICIN; FAS ANTIGEN; PROTEIN BCL 2;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031830149     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043870     Document Type: Article

References (33)

1. Fisher, D. E.: Apoptosis in cancer therapy: crossing the threshold. Cell 78 (1994) 539-542
2. Trauth, B. C., C. Klas, A. M. J. Peter, S. Matz, P. Möller, W. Falk, K.-M. Debatin, P. H. Krammer: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245 (1989) 301-305
3. Oehm, A., I. Behrmann, W. Falk, M. Pawlita, G. Maier, C. Klas, M. Li-Weber, S. Richards, J. Dhein, B. C. Trauth, H. Ponstingl, P. H. Krammer: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J. Biol. Chem. 267 (1992) 10709-10715
4. Debatin, K.-M.: Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. Cell Death Differ. 3 (1996) 185-189
5. Nagata, S.: Apoptosis by death factor. Cell 88 (1997) 355-365
6. Peter, M. E., F. C. Kischkel, S. Hellbrandt, A. M. Chinnaiyan, P. H. Krammer, V. M. Dixit: CD95 (APO-1/Fas)-associating signaling proteins. Cell Death Differ. 3 (1996) 161-170
7. Muzio, M., A. M. Chinnaiyan, F. C. Kischkel, K. O'Rourke, A. Shevchenko, J. Ni, C. Scaffidi, J. D. Bretz, M. Zhang, R. Gentz, M. Mann, P. H. Krammer, M. E. Peter, V. M. Dixit: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85 (1996) 817-827
8. Suda, T., T. Takahashi, P. Golstein, S. Nagata: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75 (1993) 1169-1178
9. Tanaka, M., T. Suda, T. Takahashi, S. Nagata: Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14 (1995) 1129-1135
10. Krammer, P. H., J. Dhein, H. Walczak, I. Behrmann, S. Mariani, B. Matiba, M. Fath, P. T. Daniel, E. Knipping, M. O. Westendorp, K. Stricker, C. Baeumler, S. Hellbardt, M. Germer, M. E. Peter, K.-M. Debatin: The role of APO-1-mediated apoptosis in the immune system. Immunol. Rev. 142 (1994) 175-191
11. Friesen, C., I. Herr, P. H. Krammer, K.-M. Debatin: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2 (1996) 574-577
12. Fulda, S., H. Sieverts, C. Friesen, I. Herr, K. M. Debatin: The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57 (1997) 3823-3829
13. Fulda, S., M. Los, C. Friesen, K.-M. Debatin: Chemosensitivity of solid tumor cells is related to activation of the CD95 system. Int. J. Cancer 76 (1998) 105-114
14. Fulda, S., C. Scaffidi, T. Pietsch, P.H. Krammer, M.E. Peter, K.-M. Debatin: Activation of the CD95 (APO-1/Fas) pathway in drug- and g-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. in press
15. Fulda, S., C. Friesen, M. Los, C. Scaffidi, W. Mier, M. Benedict, G. Nunez, P. H. Krammer, M. E. Peter, K.-M. Debatin: Betulinic acid trigers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 57 (1997) 4956-64
16. Debatin, K.-M.: Anticancer drugs, programmed cell death and the immune system: defining new roles in an old play. J. Natl. Cancer Inst. 89 (1997) 750-751
17. Müller, M., S. Strand, H. Hug, E.-M. Heinemann, H. Walczak, W. J. Hofmann, W. Stremmel, P. H. Krammer, P. R. Galle: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99 (1997) 403-413
18. Nicoletti, I., G. Migliorati, M. C. Pagliacci, F. Grignani, C. Riccardi: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 (1991) 271-279
19. Scaffidi, C., J.P. Medema, , P.H. Krammer, M.E. Peter: FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 272 (1997) 26953-26958
20. Friesen, C., S. Fulda, K.-M. Debatin: Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11 (1997) 1833-1841
21. Los, M., M. Van de Craen, L. C. Penning, H. Schenk, M. Westendorp, P. A. Baeuerle, W. Droege, P. H. Krammer, W. Fiers, K. Schulze-Osthoff: Requirement of an ICE/Ced-3 protease for Fas/APO-1-mediated apoptosis. Nature 375 (1995) 81-83
22. Los, M., I. Herr, C. Friesen, S. Fulda, K. Schultze-Osthoff, K.-M. Debatin: Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 8 (1997) 3118-3129
23. Chinnaiyan, A. M., K. O'Rourke, M. Tewari, V. M. Dixit: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81 (1995) 505-12
24. Kroemer, G.: The protooncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 3 (1997) 614-620
25. Lowe, S. W., S. Bodis, A. McClatchey, I., Remington, H. E. Ruley, D. E. Fisher, D. E. Housman, T. Jacks: p53 status and the efficacy of cancer therapy in vivo. Science 266 (1994) 807-810
26. Miyashita, T., J.C. Reed: Tumor suppressor p53 is a direct transcriptional activator of the human hax gene. Cell 80: (1995) 293-299
27. Milner, J.: DNA damage, p53 and anticancer therapies. Nat. Med. 1 (1995) 879-880
28. Herr, I., T. Boehler, D. Wilhelm, P. Angel, K.-M. Debatin: Activation of the CD95 (APO-1/Fas) pathway by ceramide mediates radio- and chemtherapy-induced apoptosis. EMBO J. 16 (1997) 6200-6208
29. Owen-Schaub, L. B., W. Zhang, J. C. Cusack, L. S. Angelo, S. M. Santee, T. Fujiwara, J. A. Roth, A. B. Deisseroth, W. W. Zhang, E. Kruzel, R. Radinsky: Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 15 (1995) 3032-3040
30. Kluck, R. M., E. Bossy-Wetzel, D. R. Green, D. D. Newmeyer: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
31. Yang, J., X., Lui, K. Bhalla, C. N. Kim, A. M. Ibrado, J. Cai, T. I. Peng, D. P. Jones, X. Wang: Prevention of apoptosis hy Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997) 1129-1132
32. Eischen, C.M., T. J. Kottke, L. M. Martins, G. S. Basi, J. S. Tung, W. C. Earnshaw, P. J. Leibson, S H. Kaufmann: Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90 (1997) 935-943
33. Villunger A., A. Egle, M. Kos, B. L. Hartmann, S. Geley, R. Kofler, R. Greil: Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-cute lymphatic leukemia cells. Cancer Res. 57 (1997) 3331-3334